More Than Two Decades in Peptide Research and Synthesis
Celtek Peptides is part of Celtek Bioscience, LLC, a Tennessee biotechnology company with a history dating to 2002.
Celtek’s work has included custom peptide synthesis, contract research, intracellular peptide delivery, cell-penetrating peptides, and the development of experimental peptide technologies. Public business records list Celtek Bioscience as beginning operations in March 2002 and identify Dr. Yao-Zhong Lin, PhD, as company management and principal contact.
Today, Celtek Peptides continues that focus through research peptide supply, custom peptide synthesis, analytical verification, and scientific information for the research community.
Our approach is based on a simple idea: researchers should know what material they are working with and should be able to see the analytical evidence behind it.
Our History
Celtek Bioscience was established during a period when cell-penetrating peptides and intracellular delivery systems were becoming increasingly important areas of biotechnology research.
From its early years, the company focused on technologies designed to move biologically active molecules into cells and influence intracellular pathways.
An archived company profile from the U.S. small-business research ecosystem described Celtek Bioscience as a biotechnology company focused on cell-delivery-based technologies, including intracellular delivery of peptides, proteins, and oligonucleotides. It also recorded Celtek’s work providing contract research services to academic and industrial researchers.
That combination of peptide chemistry and biological research became an important part of Celtek’s identity.
Early Research in Intracellular Peptide Delivery
One of Celtek’s core scientific interests was the use of peptides to cross biological membranes and affect targets inside cells.
This is a challenging problem.
Many biologically interesting molecules cannot easily pass through the cell membrane. Researchers have therefore spent decades studying sequences that can act as carriers or help deliver functional molecules into cells.
Celtek’s research centered in part on cell-permeable peptides designed to combine intracellular delivery with biological activity.
The company’s early research programs included projects involving NF-κB signaling and peptide-based approaches to intracellular targeting. Historical SBIR records list Phase I research projects in 2003 and 2004 involving enhancement of cancer therapy through NF-κB inhibition and a peptide inhibitor investigated in relation to Alzheimer’s disease.
The Development of CB5005
One of the best-documented examples of Celtek’s research history is CB5005.
CB5005 is a synthetic 21-amino-acid peptide designed to combine two functions:
- cell and membrane penetration
- inhibition of intracellular NF-κB signaling.
Celtek Bioscience and researchers Yao-Zhong Lin and Claudia Budu were associated with patent work covering cell-permeable peptide agents designed to inhibit anti-apoptotic NF-κB pathways.
A U.S. patent for this work was granted in 2008, with Celtek Bioscience, LLC listed as the assignee and Yao-Zhong Lin and Claudia Budu as inventors. CB5005 appears within the associated patent family as one of the synthesized peptide sequences.
The patent literature also describes Celtek’s use of conventional solid-phase peptide synthesis, reverse-phase HPLC purification, analytical HPLC, and mass spectrometry in the preparation and characterization of experimental peptides.
CB5005 in Published Research
CB5005 later became the subject of several peer-reviewed research projects.
A 2016 study in Acta Biomaterialia investigated CB5005 as a functionalized cell-penetrating peptide in glioma models. The publication specifically states that CB5005 was developed and provided by Celtek Bioscience, LLC.
Researchers studied whether the peptide could improve transport into brain endothelial and glioma cells while also affecting NF-κB signaling.
The work was preclinical. It involved cellular models and animal research rather than human clinical trials.
That distinction matters. Celtek’s research history demonstrates peptide-design and experimental-development work, but preclinical findings should never be presented as established human therapeutic results.
Continued Glioma Research
CB5005 was studied again in a 2018 paper published in the Journal of Controlled Release.
Researchers conjugated CB5005 to PEGylated liposomes carrying doxorubicin and investigated whether the peptide-modified system could improve penetration into glioma cells and tumors.
The study reported improved cellular uptake and penetration in experimental models, along with enhanced delivery of doxorubicin into the cell nucleus. Animal experiments also investigated the modified liposomes in mouse glioblastoma models.
Dr. Yao-Zhong Lin was listed with a Celtek Bioscience affiliation in Franklin, Tennessee.
Again, these were experimental findings rather than evidence of an approved treatment.
Research Beyond Glioma
The CB5005 research program later expanded into other experimental drug-delivery models.
A 2020 paper in Molecular Pharmaceutics studied CB5005-modified liposomal irinotecan in models of non-small-cell lung cancer.
The paper included Yao-Zhong Lin among the authors and listed Celtek Bioscience, LLC as an affiliation. Researchers investigated the combined tumor-penetrating and NF-κB-inhibitory properties of the peptide-modified delivery system.
This work continued a research theme visible throughout Celtek’s history: using peptide design not simply to create a molecule, but to study how molecular structure can influence intracellular delivery and biological function.
A History of Custom Peptide Synthesis
Celtek’s history is not limited to its own experimental peptide programs.
Custom peptide synthesis and contract research have also been part of the company since its early years.
Historical company records list services including:
- custom peptide synthesis
- custom gene synthesis
- contract research
- intracellular delivery research.
Celtek Peptides has also been named as a peptide supplier in peer-reviewed scientific publications.
For example, published research has documented the use of Celtek-supplied peptides in studies involving bacterial single-stranded DNA-binding proteins and in research involving peptide-conjugated ruthenium complexes.
That history matters because custom peptide synthesis is not simply a matter of producing a sequence.
Researchers need to consider:
- sequence feasibility
- synthesis chemistry
- purification
- purity requirements
- molecular identity
- modifications
- analytical characterization
- stability.
Those same principles continue to guide Celtek’s custom peptide work.
Custom Peptide Synthesis Today
Celtek Peptides provides custom peptide synthesis for academic, biotechnology, pharmaceutical, and other qualified research organizations.
Projects can vary substantially in scale and complexity.
Capabilities may include:
- standard peptide sequences
- different purity specifications
- milligram and larger-scale synthesis
- longer peptide sequences
- unusual amino acids
- phosphorylation
- biotinylation
- terminal modifications
- cyclic peptides
- HPLC purification
- HPLC analysis
- mass spectrometry.
Every sequence presents its own chemistry, so difficult or highly modified projects are reviewed individually.
Researchers can learn more on our Custom Peptide Synthesis page.
Quality Verification
Quality claims are only useful when they can be supported by analytical information.
Celtek’s current research peptide program uses independent analytical testing and lot-specific documentation.
Depending on the product or project, analytical characterization may include:
HPLC, which provides information about chromatographic purity.
Mass spectrometry, which provides evidence supporting molecular identity.
These methods answer different questions and should not be treated as interchangeable.
A high HPLC purity percentage alone does not prove peptide identity. Likewise, an expected molecular mass does not by itself establish chromatographic purity.
That is why Celtek emphasizes both identity and purity information where appropriate.
Researchers can learn more about our approach on the Peptide Quality Standards page.
Lot-Specific Documentation
Modern research material should be traceable.
Celtek assigns research peptide batches lot identifiers so analytical reports can be connected to the corresponding material.
The goal is for researchers to be able to follow a clear chain:
Product → Lot → Analytical Report
Rather than relying only on a generic statement such as “99% pure,” researchers should be able to examine the analytical documentation available for the specific batch.
Research and Education
Celtek Peptides is also building a scientific reference library covering peptide chemistry, analytical testing, stability, pharmacology, and emerging peptide research.
Our research content focuses on subjects such as:
- peptide structure and function
- peptides versus proteins
- receptor signaling
- HPLC
- LC-MS and mass spectrometry
- peptide purity
- peptide identity
- lyophilization
- degradation pathways
- stability testing
- in-vitro and in-vivo research
- interpretation of animal studies
- clinical trial evidence
- investigational peptides.
Emerging compounds receive special attention because the quality of information surrounding them can vary substantially.
For investigational molecules such as retatrutide, Celtek’s research content distinguishes between:
- preclinical experiments
- peer-reviewed human trials
- company-reported clinical results
- regulatory approval.
Those distinctions help prevent early research findings from being presented as stronger evidence than they actually are.
Scientific Evidence Comes in Different Levels
One principle guides much of our educational work:
Not all evidence means the same thing.
A result observed in a cultured cell does not establish that the same effect will occur in an animal.
An animal study does not automatically predict a human outcome.
A Phase 2 clinical trial does not carry the same evidentiary weight as a completed Phase 3 development program.
And an investigational peptide is not the same thing as an FDA-approved medicine.
We try to make those distinctions clear throughout Celtek’s research library.
Research Use Only
Celtek Peptides supplies research materials for in-vitro laboratory research and development use only unless expressly stated otherwise for a particular service or material.
Research-use-only peptides are not:
- approved drugs
- dietary supplements
- foods
- cosmetics
- intended for human administration
- intended for veterinary administration
- intended for diagnostic or therapeutic use.
Analytical testing such as HPLC and mass spectrometry does not change the regulatory status of a research material.
A research peptide can be analytically characterized while still being unsuitable and unauthorized for human use.
Our Approach
Celtek’s history spans peptide synthesis, intracellular delivery research, peptide development, analytical characterization, and collaboration with academic researchers.
The technology has changed during that time.
Analytical methods have improved. Peptide therapeutics have become a much larger part of pharmaceutical research. New generations of peptide agonists, conjugates, delivery systems, and modified sequences continue to appear.
But several basic principles remain the same.
Know what molecule you are working with.
Characterize it appropriately.
Understand what the analytical data actually show.
Distinguish experimental findings from established clinical evidence.
And document the material well enough that another researcher can understand what was used.
Those principles are the foundation of Celtek Peptides.
Explore Celtek
Custom Peptide Synthesis
Learn about custom sequences, purification options, modifications, quantities, and analytical testing.
Peptide Quality Standards
Learn how HPLC, mass spectrometry, lot tracking, and Certificates of Analysis are used to characterize research peptides.
Articles & Research
Explore Celtek’s growing library covering peptide chemistry, analysis, stability, pharmacology, and emerging research.
Retatrutide Research
Review current peer-reviewed and clinical research on the investigational triple-receptor agonist retatrutide.
Contact Celtek
Contact us regarding research materials, custom synthesis, analytical questions, or research projects.
For Research Use Only. Not for human or veterinary use.